Pharmaceutical companies eager to keep less expensive alternatives to their drugs off the market are increasingly reaching legal agreements with generic drugmakers to accomplish that goal, a government agency said Wednesday.
More than 30 patent lawsuits were settled in the 12 months ending last Sept. 30 between brand-name drug companies and generic manufacturers, the Federal Trade Commission said. Fourteen of those settlements included both a restriction on the generic company’s ability to market a drug and compensation to the generic manufacturer, the agency said in an annual report.
